Building Australia's sovereign RNA and DNA manufacturing
Human grade DNA and RNA manufacturing is concentrated in a small number of countries. Syngenis is bringing that capability onshore, with Australia's only commercial RNA facility.
Human grade DNA and RNA manufacturing is concentrated in a small number of countries, leaving Australia and the wider Asia Pacific region structurally under supplied. Syngenis was created to close that gap and build long term, sovereign capacity in DNA and RNA technologies.
Keeping DNA and RNA work in Australia protects intellectual property, reduces lead times, and can support R&D Tax Incentive claims of up to 43.5 percent of eligible spend, without the need for an Advance Overseas Finding. Australia returns up to 43.5 cents in every eligible research and development dollar as a refundable cash offset, one of the most generous innovation incentives in the world.
Our research grade facility is operational and generating revenue today, and our human grade facility is in build, targeted for 2027 subject to commissioning, validation and regulatory readiness. Together they form the manufacturing pillar of an integrated life sciences company.
Bring your program to Syngenis
Talk to our team about your program, from candidate design to trial ready material.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.